Antibiotic Treatment Versus no Therapy in Kidney Transplant Recipients With Asymptomatic Bacteriuria
NCT ID: NCT01771432
Last Updated: 2015-06-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
200 participants
INTERVENTIONAL
2013-01-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Outcomes of Empiric Antibiotic Therapy Based on Hospital Antibiograms in Organ Transplant Recipients with Bacteraemia
NCT06874920
Does the National Health Insurance Card Allow us to Predict Antibiotic Resistance?
NCT02292160
Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis
NCT01345929
Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients
NCT02729116
Antimicrobial Susceptibility for Helicobacter Pylori Eradication
NCT01486082
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Measurements: Urine cultures will be collected weekly during the first month after transplantation, every 2 weeks until three months after transplantation, every month until 6 months after transplantation and every 3 months until 12 months after transplantation. Urine culture will be as well collected if urinary symptoms appeared.
Primary end points: To determine in both groups: the incidence of pyelonephritis.
Secondary end points: To determine outcomes in both groups (renal function, hospitalization, rejection, graft loss, opportunistic infections and mortality) and infection by multiresistant microorganisms.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Antibiotic treatment
Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics.
Antibiotic treatment
Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics
No treatment
Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
No treatment
Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Antibiotic treatment
Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics
No treatment
Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Núria Sabé Fernàndez
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Núria Sabé Fernàndez
Infectious Diseases Phisycian
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Núria Sabé Fernàndez
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitari de Bellvitge
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Vall d'Hebron
Barcelona, Barcelona, Spain
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FIS11-1540
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.